

For professional clients only – not for distribution to retail clients.

Fund Aim

The fund aims to provide long-term capital growth through investment primarily in Continental European equities.

TOP 10 HOLDINGS

1.	Anheuser-Busch	7.6%
2.	Novo Nordisk	6.8%
3.	Bayer	5.9%
4.	SAP	5.9%
5.	Crayon Group	4.3%
6.	Unicaja Banco	3.3%
7.	STRABAG	3.0%
8.	Pareto Bank	2.8%
9.	OMV	2.8%
10.	BBVA	2.3%

PERFORMANCE

	Class B EUR	STOXX Europe 600 ex UK
3 months	1.1%	4.4%
6 months	10.4%	17.5%
12 months	-4.8%	5.9%
Since launch (11 Sept. 2015)	18.6%	22.8%

	Class B EUR	STOXX Europe 600 ex UK
2019 YTD	10.4%	17.5%
2018	-16.4%	-10.9%
2017	13.9%	11.6%
2016	8.6%	2.4%
2015 (from 11 Sept.)	4.0%	2.6%

Commentary

In June the Comeragh European Growth Fund rose 4.7% vs. the increase of 5.1% recorded by the market.


Markets rebounded strongly over the month, buoyed by increasingly dovish comments from both the Federal Reserve and the ECB. In response to weakening economic data, Jerome Powell indicated that the Fed would “act as appropriate to sustain the expansion” while Mario Draghi paved the way for additional stimulus and asset purchases. The market is pricing in a July Fed rate cut and several more to come over the coming quarters, meanwhile having already bought €2.6 trillion worth of debt securities and so reduced the supply of “safe” assets, the ECB would likely have to move out along the risk curve should asset purchases be restarted. At the prospect of such monetary largesse, markets have regained their highs even as the evidence for a global slowdown mounts. Investors appear to be placing a lot of confidence in the “central bank put”. Recent historical experience, however, favours a less sanguine perspective. Far from sustaining the expansion, a loosening of monetary policy has typically preceded – or been coincident with – recessions and bear markets.

Bayer was a positive contributor, rising 8% in one day as news broke that activist investor Elliott had taken a stake and would push for a settlement in the ongoing Roundup litigation. Despite solid operating performance and


robust earnings momentum, Bayer has lost around €50bn in market capitalisation over the last year as this case has dominated the headlines. A settlement, even if costly, would likely see a significant re-rating. Negative contributors this month include Adler Real Estate, the German residential property owner, which underperformed on news that Berlin was proposing a five-year rent freeze. Adler has minimal exposure to Berlin (<5% of assets) and there are question markets over the legality of the proposal – but with public anger around rent levels growing, the market is jittery lest such policies proliferate. A speedy end to the political rumblings appears unlikely, but in the meantime Adler shares trade on a 50% discount to NAV, despite its property portfolio seeing rental growth and increased occupancy. As LTV falls, the achievement of investment grade status should pave the way for dividends, a move that would help unlock the latent value on offer.

Cautious of richly valued markets and deteriorating global macro, we retain a cash position of nearly 10% in the Fund. Meanwhile certain intra-market dynamics have reached extreme levels. The “value” segments of the market, despite no relative deterioration in profitability, have fallen to all-time valuation lows relative to “secure growth” stocks. We believe an inflection point is upon us and are adding to select franchises accordingly.

Sector Allocation



Country Allocation



Risk Overview

	FUND	INDEX
P/E	12.7	15.7
EV/EBITDA	7.0	9.1
Div Yield	3.9%	3.7%
ROE	17.8%	15.8%
3m EPS Revs	1.7%	1.5%
Net Debt / EBITDA	0.72	1.00
Sharpe Ratio	-0.37	
Beta (3m)	0.98	

Fund Facts

Fund Status	Sub-fund of a Dublin-domiciled UCITS ICAV, authorised and regulated by the Central Bank of Ireland. Recognised in the UK by the Financial Conduct Authority
Sector	Europe ex UK
Benchmark Index	STOXX Europe 600 ex UK
Fund Size	€51.3m
Fund Launch Date	11 th September 2015

Class	ISIN	SEDOL	Distribution Type	Annual Management Fee	Initial Minimum Subscription
Class A EUR	IE00BYN38431	BYN3843	Income	0.60%	€100,000
Class A GBP Hedged	IE00BYN38985	BYN3898	Income	0.60%	£100,000
Class B EUR	IE00BYN38M12	BYN38M1	Accumulation	0.60%	€100,000
Class B GBP Hedged	IE00BYN38Q59	BYN38Q5	Accumulation	0.60%	£100,000
Class C EUR	IE00BYN38Y34	BYN38Y3	Income	0.75%	€500
Class C GBP Hedged	IE00BYN39629	BYN3962	Income	0.75%	£500
Class D EUR	IE00BYN39B71	BYN39B7	Accumulation	0.75%	€500
Class D GBP Hedged	IE00BYN39C88	BYN39C8	Accumulation	0.75%	£500

Further Information

Email: info@comeraghcapital.com

Website: www.comeraghcapital.com

Telephone: +44 (0) 207 381 5022

Dealing:

- Daily dealing (except Irish public holidays)
- 11.00 dealing cut-off (forward pricing)
- 17.00 valuation point
- CACEIS Ireland
 - + 353 (0)1 672 1631
 - One Custom House Plaza, IFSC, Dublin D01 C2C5, Ireland

Risk Warning

The value of investments and the income from them can go down as well as up and investors may not receive back the original amount invested. Past performance is not an indicator of future performance. Exchange rates may cause the value of the underlying overseas investments to go down as well as up. Investment in smaller companies may involve a higher degree of risk as markets are usually more sensitive to price movements.

Please read the Risk Section of the Fund's Prospectus and Key Investor Information Document (KIID) for a fuller description of the risks prior to investing. Comeragh Capital LLP and its affiliates and/or their officers, partners and employees may own or have positions in the fund and/or any investment mentioned herein. The factsheet does not represent an invitation to invest in the Fund. Subscriptions must be made in conjunction with the KIID and Prospectus, copies of which can be obtained free of charge in English at www.comeraghcapital.com. Comeragh Capital LLP acts as investment manager and promoter to Comeragh Funds ICAV.